Metabolic
Syndrome
For one of the fastest growing areas of disease we offer a variety of pharmaceutical products that target different aspects of this multifactorial disease.
The ‘Novofylline’
Puroxan®, Axofin®, Asima®
For Asthma and COPD
Available in Tablets and Syrup
Indication:
• Asthma
• COPD
• Bronchitis
Unique Selling points:
• Bronchodilation
• Anti-inflammatory
• Prevention of Bronchospasm
• Better safety profile than Theophylline
• Wide therapeutic window
• Steroid sparing effect